Is GW Pharmaceuticals PLC- ADR (GWPH) Stock Outperforming or Underperforming?

Friday, May 22, 2020 1:42 PM | InvestorsObserver Analysts

The 24 rating InvestorsObserver gives to GW Pharmaceuticals PLC- ADR (GWPH) stock puts it near the middle of the Healthcare sector.

In addition to scoring higher than 39 percent of stocks in the Healthcare sector, GWPH’s 24 overall rating means the stock scores better than 24 of all stocks.

Overall Score - 24
GWPH has an Overall Score of 24. Find out what this means to you and get the rest of the rankings on GWPH!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style.

Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With GW Pharmaceuticals PLC- ADR Stock Today?

GW Pharmaceuticals PLC- ADR (GWPH) stock is trading at $125.92 as of 1:39 PM on Friday, May 22, a gain of $0.67, or 0.53% from the previous closing price of $125.25. The stock has traded between $124.08 and $128.93 so far today. Volume today is light. So far 200,802 shares have traded compared to average volume of 410,464 shares.

To see the top 5 stocks in Healthcare click here.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Is Global Cord Blood Corp (CO) Stock a Great Value?

Denali Therapeutics Inc (DNLI) Stock Climbs 10.58% This Week; Should You Buy?

Should Replimune Group Inc (REPL) Stock be in Your Portfolio?

Should You Buy AcelRx Pharmaceuticals Inc (ACRX) Stock?

Sector Update: Health Care Stocks Slipping in Late Trade

Related Companies